TTrialPathMatch Me to Trials
← Back to trials
RecruitingNasal PolypsStaphylococcus Aureus

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP

Eligible age

18–65 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity. Primary Objective will be to demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance while increasing microbial diversity in patients with CRSwNPs who are culture positive for staph aureus at enrollment. Secondary Objectives will be to correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. In addition, the investigators will correlate improvements in microbial diversity/decreased staph abundance with clinical improvements as assessed via questionnaires and objective/subjective smell function and also as improvements in cellular/immune T2 inflammation as assessed by reduced expression of T2 cytokines/chemokines and eosinophil/eosinophil-derived proteins.

Sponsor: University of Virginia

You may qualify if…

  • ✓ History of CRSwNP including subjects with AERD
  • ✓ Sinonasal culture demonstrating staph aureus at visit 1
  • ✓ History of FESS with patent sinus ostia sufficient to obtain culture and tissue samples from the middle meatus
  • ✓ Asthma, if present, should be well controlled
  • ✓ Atopic dermatitis, if present, should be well controlled
  • ✓ Use of nasal saline irrigation and stable dosing (\>1 month) of topical corticosteroids is permitted
  • ✓ Intent of the physicians caring to start dupilumab therapy as part of subject's standard of care
  • ✓ Subject meets FDA approved criteria for the use of dupilumab for nasal polyps

You may not qualify if…

  • ✕ Concurrent serious medical problem
  • ✕ Uncontrolled asthma (ACT \<20 at screening visit)
  • ✕ Recent (within 60 days) use of oral corticosteroids
  • ✕ Recent (within 60 days) urgent care, ED visit, or hospitalization for asthma
  • ✕ Current smoker or has smoked \>10 pack-years
  • ✕ Biologic therapy including asthma biologic therapy in last 3 months
  • ✕ Recent (within 1 month) change in CRS medical treatment (topical steroids, surfactants, irrigation protocol, etc. including changes in delivery volume or delivery methodology)
  • ✕ Recent (within 6 weeks) upper respiratory infection

Where it's recruiting

Virginia

Charlottesville

Source: ClinicalTrials.gov · NCT05094570 · last updated 2025-04-01

Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Coloniz · TrialPath